TerminatedNot Applicable

NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice

Stopped: Sponsor decision

Russia6 participantsStarted 2025-07-29

Plain-language summary

This is a prospective, non-interventional, multicenter study to evaluate the efficacy and safety of iptacopan in patients with PNH in real-world settings in Russia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years at the start of iptacopan therapy.
✓. The patient is undergoing treatment with iptacopan.
✓. The treating physician decided to prescribe iptacopan based on the Summary of Product Characteristics during routine clinical practice, regardless of study participation.
✓. Provision of written informed consent.

What they're measuring

Number of patients with an increase in Hb level ≥ 20 g/l

Timeframe: 6 months

Trial details

NCT IDNCT07036718

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-12-25

View on ClinicalTrials.gov More Paroxysmal Nocturnal Hemoglobinuria trials